DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Ieq Capital LLC

Ieq Capital LLC reduced its stake in DexCom, Inc. (NASDAQ:DXCMGet Rating) by 17.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,547 shares of the medical device company’s stock after selling 3,971 shares during the period. Ieq Capital LLC’s holdings in DexCom were worth $1,494,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of DXCM. Crewe Advisors LLC acquired a new stake in shares of DexCom in the second quarter valued at $26,000. Sound Income Strategies LLC raised its stake in shares of DexCom by 300.0% in the third quarter. Sound Income Strategies LLC now owns 320 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 240 shares in the last quarter. Bivin & Associates Inc. raised its stake in shares of DexCom by 300.0% in the second quarter. Bivin & Associates Inc. now owns 360 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 270 shares in the last quarter. Ronald Blue Trust Inc. raised its stake in shares of DexCom by 860.5% in the third quarter. Ronald Blue Trust Inc. now owns 365 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 327 shares in the last quarter. Finally, Private Trust Co. NA acquired a new stake in DexCom in the second quarter valued at $29,000. 94.01% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at DexCom

In related news, Director Steven Robert Pacelli sold 412 shares of the firm’s stock in a transaction dated Friday, December 23rd. The shares were sold at an average price of $112.57, for a total value of $46,378.84. Following the completion of the sale, the director now owns 137,288 shares in the company, valued at $15,454,510.16. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, EVP Paul R. Flynn sold 8,988 shares of DexCom stock in a transaction that occurred on Thursday, December 8th. The shares were sold at an average price of $123.50, for a total transaction of $1,110,018.00. Following the completion of the sale, the executive vice president now directly owns 55,744 shares in the company, valued at approximately $6,884,384. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Steven Robert Pacelli sold 412 shares of DexCom stock in a transaction that occurred on Friday, December 23rd. The shares were sold at an average price of $112.57, for a total transaction of $46,378.84. Following the sale, the director now owns 137,288 shares of the company’s stock, valued at $15,454,510.16. The disclosure for this sale can be found here. Insiders sold a total of 57,819 shares of company stock worth $6,294,063 over the last 90 days. Company insiders own 0.41% of the company’s stock.

DexCom Stock Performance

NASDAQ DXCM opened at $106.03 on Wednesday. The company has a quick ratio of 3.43, a current ratio of 3.77 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a 52-week low of $66.89 and a 52-week high of $134.76. The business’s 50-day moving average price is $112.85 and its 200 day moving average price is $99.36. The firm has a market cap of $40.96 billion, a P/E ratio of 195.45, a P/E/G ratio of 2.91 and a beta of 1.14.

DexCom (NASDAQ:DXCMGet Rating) last announced its quarterly earnings data on Thursday, October 27th. The medical device company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. The firm had revenue of $769.60 million during the quarter, compared to the consensus estimate of $752.67 million. DexCom had a net margin of 8.24% and a return on equity of 13.27%. On average, equities research analysts expect that DexCom, Inc. will post 0.79 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on DXCM shares. Cowen raised their price target on DexCom from $85.00 to $114.00 in a research note on Friday, October 28th. Morgan Stanley raised their price target on DexCom from $117.00 to $131.00 and gave the company an “equal weight” rating in a research note on Friday, January 6th. Robert W. Baird raised their price target on DexCom from $97.00 to $120.00 in a research note on Friday, October 28th. Barclays started coverage on DexCom in a research note on Monday, October 17th. They issued an “equal weight” rating and a $103.00 price target on the stock. Finally, Stifel Nicolaus raised their price target on DexCom from $120.00 to $130.00 in a research note on Tuesday, December 20th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $122.00.

DexCom Company Profile

(Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Featured Articles

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.